ReviewFrontiers in immunology2025
Upadacitinib successfully treats Hailey-Hailey disease: a cases report and literature review.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Short-term disease control with alternate-day maintenance upadacitinib in refractory Hailey-Hailey disease: a case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hailey-Hailey disease (HHD) is a rare autosomal dominantly inherited skin disorder first described by brothers Howard and Hugh Hailey in 1939. This article reports a case of refractory Hailey-Hailey disease, which was treated with upadacitinib with remarkable efficacy after the unsatisfactory results of traditional treatment regimens. The patient was a 38-year-old male with a 2-year history of the disease. The rash improved significantly at 3 weeks of oral treatment with upadacitinib 15 mg/day and continued to improve at 12 weeks of follow-up without serious adverse effects. Together with the literature review, this study aims to investigate the efficacy and safety of the JAK inhibitor upadacitinib as a novel therapeutic regimen for Hailey-Hailey disease, and to provide a reference for the clinical treatment of refractory cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.